For more than two decades, every woman who picked up an estrogen prescription in the United States also picked up a black box. The boxed warning, the most serious caution the Food and Drug Administration can place on a drug label, listed heart disease, stroke, breast cancer and probable dementia. Many women read it and never filled the prescription. Many doctors stopped offering it.
In November 2025, that changed. The FDA announced1 that it was removing the boxed warning language on cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy products. One boxed warning remains. Estrogen-only therapy in women who still have a uterus raises the risk of endometrial cancer, which is why those women are prescribed a progestogen alongside it.
A year on, the question in exam rooms is less about whether hormone therapy is allowed and more about whether it is right for a particular woman.
How we got here
The warning traces back to July 2002, when the Women's Health Initiative stopped its estrogen plus progestin trial early. The results in JAMA2 reported more breast cancers, heart attacks, strokes and blood clots in women taking combined hormones than in women taking placebo. The news landed as a shock. Prescriptions fell sharply within months.
What got less attention was who the trial enrolled. The average participant was 63 years old, more than a decade past menopause for most. The study was designed to test whether hormones prevented chronic disease in older women, not whether they were safe for a 51-year-old with night sweats.
Over the years that followed, researchers kept reanalyzing the data by age. A 2017 follow-up in JAMA3 looked at about 18 years of mortality data from both WHI hormone trials. Hormone therapy for five to seven years was not associated with an increase in all-cause, cardiovascular or cancer death over the long run. Among the youngest women, the trend pointed toward benefit, though not decisively.
The trial was designed to test whether hormones prevented disease in older women, not whether they were safe for a 51-year-old with night sweats.
The timing idea
The concept that ties the evidence together is often called the timing hypothesis. Estrogen appears to act differently on blood vessels that are still relatively healthy than on vessels that already have significant plaque. Starting hormone therapy near menopause may carry a very different risk profile than starting it at 65.
That is reflected in the 2022 position statement4 from The North American Menopause Society, now called The Menopause Society. For healthy women younger than 60 or within 10 years of menopause onset, the society concluded that the benefits of hormone therapy generally outweigh the risks for treating bothersome hot flashes and for preventing bone loss in women at elevated risk. The balance becomes less favorable for women who start later.
Risks that have not gone away
Removing a warning box does not remove risk. It changes how risk is communicated. Women and their clinicians should still weigh several things.
Breast cancer risk with combined estrogen plus progestogen appears to rise with longer duration of use. Estrogen alone, in women without a uterus, has looked more neutral and in some analyses favorable. Oral estrogen raises the risk of blood clots more than transdermal patches or gels do, which matters for women with a history of clots or other clotting risk. A personal history of breast cancer, unexplained vaginal bleeding, active liver disease or prior stroke generally rules systemic therapy out or calls for specialist input.
Some experts criticized the speed and process of the 2025 decision, arguing it relied more on expert opinion than on new trial data. That debate is worth knowing about. It is also not a reason to return to blanket avoidance, which left millions of women suffering through symptoms that are very treatable.
What a good visit looks like
A thoughtful hormone therapy consultation is personal. It starts with symptoms and goals, which might be hot flashes, sleep disruption, vaginal dryness, mood changes or bone health. It covers family history, blood pressure, clotting risk and breast screening. It considers the route, since a patch and a pill are not interchangeable, and the dose, which is usually the lowest that works.
Local vaginal estrogen for genitourinary symptoms is its own category. It delivers very little hormone to the rest of the body and has a much simpler risk profile.
Perimenopause can begin in a woman's early forties, years before periods stop, and its first signs are often irregular cycles, poor sleep or mood changes rather than hot flashes. Women in that window often wait for symptoms to become unbearable before raising them. With the timing rules in the current evidence, an earlier conversation keeps more options open. Bring a few weeks of notes on sleep, cycles and symptoms. It makes the appointment far more productive than a general description.
